AR098693A1 - Método para producir células del epitelio pigmentario retiniano (rpe) - Google Patents

Método para producir células del epitelio pigmentario retiniano (rpe)

Info

Publication number
AR098693A1
AR098693A1 ARP140104590A ARP140104590A AR098693A1 AR 098693 A1 AR098693 A1 AR 098693A1 AR P140104590 A ARP140104590 A AR P140104590A AR P140104590 A ARP140104590 A AR P140104590A AR 098693 A1 AR098693 A1 AR 098693A1
Authority
AR
Argentina
Prior art keywords
cells
rpe
retinian
epitel
pigmentary
Prior art date
Application number
ARP140104590A
Other languages
English (en)
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR098693A1 publication Critical patent/AR098693A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un método para producir células del epitelio pigmentario retiniano (RPE) que comprende las etapas de: (a) cultivar células pluripotentes en presencia de un primer inhibidor de SMAD y un segundo inhibidor de SMAD; (b) cultivar las células de la etapa (a) en presencia de un activador de la vía de BMP y en ausencia de los primeros y segundos inhibidores de SMAD; y, (c) recolocar las células de la etapa (b) en placas. Reivindicación 124: Células RPE que se obtienen mediante un método de acuerdo con cualquiera de las reivindicaciones 1 a 123. Reivindicación 126: Una composición farmacéutica que comprende las células RPE de la reivindicación 124 ó 125. Reivindicación 127: Un método para el tratamiento de una enfermedad de la retina en un sujeto, dicho método comprende administrar las células RPE de la reivindicación 124 ó 125 o una composición farmacéutica de la reivindicación 126 a dicho sujeto.
ARP140104590A 2013-12-11 2014-12-10 Método para producir células del epitelio pigmentario retiniano (rpe) AR098693A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361914445P 2013-12-11 2013-12-11

Publications (1)

Publication Number Publication Date
AR098693A1 true AR098693A1 (es) 2016-06-08

Family

ID=52446403

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104590A AR098693A1 (es) 2013-12-11 2014-12-10 Método para producir células del epitelio pigmentario retiniano (rpe)

Country Status (13)

Country Link
EP (1) EP3080248A1 (es)
JP (1) JP2017504311A (es)
KR (1) KR101871084B1 (es)
CN (1) CN105814194A (es)
AR (1) AR098693A1 (es)
AU (1) AU2014363032A1 (es)
BR (1) BR112016012129A8 (es)
CA (1) CA2933083A1 (es)
HK (1) HK1221734A1 (es)
IL (1) IL245594A0 (es)
MX (1) MX2016007671A (es)
TW (2) TW201823451A (es)
WO (1) WO2015087231A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895626T3 (es) * 2014-11-21 2022-02-22 Rigel Pharmaceuticals Inc Derivados de imidazol condensados como inhibidores de TGF-beta
ES2774456T3 (es) * 2014-12-30 2020-07-21 Cell Cure Neurosciences Ltd Poblaciones de células del RPE y métodos de generación de las mismas
US20180008458A1 (en) * 2014-12-30 2018-01-11 Cell Cure Neurosciences Ltd. Methods of treating retinal diseases
WO2016108240A1 (en) * 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
EP3331994B1 (en) 2015-08-05 2022-09-14 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
EP3347456B1 (en) * 2015-09-08 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
CA2997763A1 (en) * 2015-09-08 2017-03-16 Cellular Dynamics International, Inc. Macs-based purification of stem cell-derived retinal pigment epithelium
ES2862676T3 (es) 2015-10-20 2021-10-07 Fujifilm Cellular Dynamics Inc Producción de células precursoras hematopoyéticas multilinaje mediante programación genética
CA3007107A1 (en) * 2015-12-04 2017-06-08 Bond University Ltd Methods of differentiating retinal cells
CN106344932B (zh) * 2016-08-26 2019-12-27 首都医科大学附属北京同仁医院 一种用于提高视网膜退行性疾病基因治疗效果的组合物及其应用
CA3210578A1 (en) 2016-12-07 2018-06-14 Mayo Foundation For Medical Education And Research Methods and materials for using fibrin supports for retinal pigment epithelium transplantation
CN106906178A (zh) * 2017-04-07 2017-06-30 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 培养上皮细胞的组合物及其保持上皮样细胞形态中的应用
WO2018226648A1 (en) * 2017-06-05 2018-12-13 Mayo Foundation For Medical Education And Research Methods and materials for culturing, proliferating, and differentiating stem cells
CN109957545A (zh) 2017-12-26 2019-07-02 江苏艾尔康生物医药科技有限公司 一种消化rpe细胞的方法
TW202012390A (zh) * 2018-06-29 2020-04-01 日商日本歐愛特農業科技股份有限公司 新穎之經取代吡唑衍生物
WO2020229628A1 (en) * 2019-05-15 2020-11-19 Novo Nordisk A/S Methods for obtaining eye field progenitor cells from human pluripotent stem cells
WO2021014515A1 (ja) * 2019-07-19 2021-01-28 東京エレクトロン株式会社 細胞の分化状態の評価方法
WO2021020282A1 (ja) 2019-07-26 2021-02-04 学校法人埼玉医科大学 Ａｌｋ２／ａｃｖｒ１の細胞外領域を認識する抗体
CN113699097B (zh) * 2021-09-08 2023-06-09 湖南光琇高新生命科技有限公司 视网膜色素上皮细胞的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49267A1 (en) 1989-08-14 1998-05-18 Photogenesis Inc Surgical instrument and cell isolation and transplantation
US6045791A (en) 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5941250A (en) 1996-11-21 1999-08-24 University Of Louisville Research Foundation Inc. Retinal tissue implantation method
US7824671B2 (en) 2002-10-04 2010-11-02 Tissuetech, Inc. Retinal pigment epithelial cell cultures on amniotic membrane and transplantation
KR20130025953A (ko) 2004-01-23 2013-03-12 어드밴스드 셀 테크놀로지, 인코포레이티드 망막 변성 질환 치료를 위한 개선된 양식
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
EP2960328A1 (en) 2004-11-04 2015-12-30 Ocata Therapeutics, Inc. Derivation of embryonic stem cells
EA014166B1 (ru) 2005-12-13 2010-10-29 Киото Юниверсити Ядерный фактор перепрограммирования
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
WO2008087917A1 (ja) 2007-01-18 2008-07-24 Riken 視細胞への分化誘導方法
AU2008231020B2 (en) 2007-03-23 2013-09-05 Wisconsin Alumni Research Foundation Somatic cell reprogramming
CN101688178B (zh) 2007-04-18 2013-12-04 哈达锡特医学研究服务及发展有限公司 干细胞衍生的视网膜色素上皮细胞
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
IL292561A (en) 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
GB0806746D0 (en) 2008-04-14 2008-05-14 Ucl Business Plc Membrane
CA2771901C (en) 2009-08-24 2020-03-10 Wisconsin Alumni Research Foundation Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same
CA2781149A1 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
ES2542226T3 (es) 2010-04-28 2015-08-03 Technische Universität Dresden Método para producir células progenitoras retinianas polarizadas a partir de células madre pluripotentes y su diferenciación para dar células del epitelio pigmentario retiniano
US9453198B2 (en) * 2010-05-25 2016-09-27 Memorial Sloan Kettering Cancer Center Method of nociceptor differentiation of human embryonic stem cells and uses thereof
GB201011313D0 (en) 2010-07-05 2010-08-18 Ucl Business Plc Implantation devices, methods and implants
JP5876045B2 (ja) 2010-07-12 2016-03-02 ユニバーシティー オブ サザン カリフォルニア 幹細胞と標的組織の相互接続を促進する生体適合性基材およびそれを埋め込む方法
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
CN102465111A (zh) * 2010-11-19 2012-05-23 薛志刚 一种体外人胚胎干细胞诱导分化为视网膜色素上皮细胞的试验方法
US10390856B2 (en) 2011-01-18 2019-08-27 Minipumps, Llc Surgical implantation instrument
WO2012177968A1 (en) 2011-06-22 2012-12-27 The Schepens Eye Research Institute, Inc. A scaffold for subretinal cell transplantation and drug delivery
SI2780022T1 (sl) 2011-11-14 2019-09-30 Astellas Institute For Regenerative Medicine Farmacevtski preparati humanih rpe celic in njihova uporaba
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
CN102618488A (zh) * 2012-03-15 2012-08-01 中国人民解放军第三军医大学第一附属医院 一种制备视网膜色素上皮细胞的方法
US9458428B2 (en) 2012-06-05 2016-10-04 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells
WO2014121077A2 (en) 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)

Also Published As

Publication number Publication date
EP3080248A1 (en) 2016-10-19
AU2014363032A1 (en) 2016-06-09
KR101871084B1 (ko) 2018-06-25
BR112016012129A2 (pt) 2017-08-08
KR20160095118A (ko) 2016-08-10
CA2933083A1 (en) 2015-06-18
CN105814194A (zh) 2016-07-27
TW201538726A (zh) 2015-10-16
WO2015087231A1 (en) 2015-06-18
BR112016012129A8 (pt) 2020-05-12
MX2016007671A (es) 2016-10-14
HK1221734A1 (zh) 2017-06-09
JP2017504311A (ja) 2017-02-09
TW201823451A (zh) 2018-07-01
IL245594A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
AR098693A1 (es) Método para producir células del epitelio pigmentario retiniano (rpe)
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CY1124311T1 (el) Παρεμποδιστες dna-pk
DOP2020000050A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017000992A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasa
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
SV2017005424A (es) Métodos para tratar infecciones por el virus filoviridae
CL2016000060A1 (es) Derivados piperidinil indol y su uso como inhibidores factor de complemento b.
NZ728072A (en) Modulators of toll-like receptors for the treatment of hiv
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
PE20151023A1 (es) Triazolopirazinas
ECSP14030779A (es) Inhibidores del nampt
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CL2014000432A1 (es) Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica.
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
CR20150211A (es) Compuestos diméricos
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk

Legal Events

Date Code Title Description
FB Suspension of granting procedure